MedTrace Logo

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

NCT07364786 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-23

No results posted yet for this study

Summary

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are:

* Will Salovum® reduce intratumoral pressure?
* Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume.

Researchers will:

* Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure.
* Compare measurements from participants before and during ingestion of Salovum®.

Participants will:

* Have probes implanted during a surgical biopsy.
* Ingest Salovum® 24 to 72 hours after the procedure.

Conditions

Interventions

DIETARY_SUPPLEMENT

Salovum

Ingestion of Salovum 11g three times daily during 48 hours

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Region Skane

    collaborator OTHER

  • Peter Siesjö

    lead OTHER

Principal Investigators

  • Peter Siesjö, MD, PhD · Skane University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2026-10-31
Completion
2026-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07364786 on ClinicalTrials.gov